{"entity":{"id":"doi-toshihiko","kind":"person","name":"Toshihiko Doi","aka":["toshihiko-doi"],"tldr":"Led the first-in-human study of trastuzumab deruxtecan and runs one of Asia's most productive phase 1 units.","summary":"Toshihiko Doi is Director of the Department of Experimental Therapeutics at the National Cancer Center Hospital East in Japan. He runs one of Asia's most productive phase 1 units and led the first-in-human study of DS-8201, the Daiichi Sankyo antibody-drug conjugate now known as trastuzumab deruxtecan, along with numerous other first-in-class studies in solid tumours. His publications include the phase 1 dose-escalation study of trastuzumab deruxtecan in patients with advanced breast and gastric or gastro-oesophageal tumours. His interests are phase 1 trials, drug development, gastrointestinal oncology and antibody-drug conjugates. He also directs National Cancer Center Hospital East in Kashiwa, one of the main sites for first-in-human oncology trials in Japan, and led pivotal work on trastuzumab deruxtecan and trifluridine/tipiracil in gastric cancer.","asOf":"2026-09-08","links":[{"label":"National Cancer Center Hospital East","url":"https://www.ncc.go.jp/en/ncce/index.html"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Doi%20T%5BAuthor%5D%20National%20Cancer%20Center%20Hospital%20East%20phase%201"},{"label":"Hospital director greeting","url":"https://www.ncc.go.jp/en/ncce/about/greeting/index.html"}],"tags":["leadership","clinician-scientist","gastric cancer","drug development"],"related":[],"cancers":["gastric","esophageal"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["trastuzumab-deruxtecan"],"companies":["daiichi-sankyo"],"institutions":["ncc-japan","ncc-hospital-east"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Department of Experimental Therapeutics, National Cancer Center Hospital East","institutionId":"ncc-japan","specialisms":["Phase 1 trials","Drug development","Gastrointestinal oncology","Antibody-drug conjugates","Gastric cancer"],"profiles":[{"label":"National Cancer Center Hospital East","url":"https://www.ncc.go.jp/en/ncce/index.html"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Doi%20T%5BAuthor%5D%20National%20Cancer%20Center%20Hospital%20East%20phase%201"},{"label":"Hospital director greeting","url":"https://www.ncc.go.jp/en/ncce/about/greeting/index.html"}],"papers":[{"title":"Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study","journal":"Lancet Oncology","year":2017,"doi":"10.1016/S1470-2045(17)30604-6"},{"title":"Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial","journal":"Lancet Oncology","year":2018,"doi":"10.1016/S1470-2045(18)30739-3"},{"title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study","journal":"Lancet Oncology","year":2019,"doi":"10.1016/S1470-2045(19)30088-9"}]},"route":"/people/doi-toshihiko/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"company":[{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"}],"institution":[{"id":"ncc-japan","kind":"institution","name":"National Cancer Center Hospital","route":"/institutions/ncc-japan/"},{"id":"ncc-hospital-east","kind":"institution","name":"National Cancer Center Hospital East","route":"/institutions/ncc-hospital-east/"}]}}